Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors
CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that onJanuary 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center inChina,...
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refrac...
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell le...
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
SHENZHEN, China, April 16, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences , aChina headquartered biopharmaceutical company developing and marketing novel drugs based on its unique technology of Chemical Genomics Drug discovery platform, today announces that it has received Investigational Ne...
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.
SHENZHEN, China, Jan. 11, 2021 /PRNewswire/ -- On January 8, 2021, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted its pivotal phase III clinical trial application (IND) of national class I innovative drug Chiauranib to NMPA, for the treatment...
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"
SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III cl...
Chipscreen and HISUN reach a strategic cooperation
SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) andZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a s...
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, March 24, 2020 /PRNewswire/ -- On March 23th, 2020, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's application for Investigational New Drug (IND) of CS12192 has been accepted by Center for Drug Evaluation, ...
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
SHENZHEN, China, Nov. 29, 2019 /PRNewswire/ -- On November 29, 2019, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Epidaza® (Chidamide), an oral subtype-selective histone deacetylase (HDAC) inhib...
Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
SHENZHEN, China, Sept. 19, 2019 /PRNewswire/ -- The new drug application (NDA) of Chiglitazar (Bilessglu®), an innovative new chemical entity (Category 1 c hemical drug) for type 2 diabetes discovered and developed by Shenzhen Chipscreen Biosciences (Stock Symbol: 688321.SH), has been accepted by ...
